Entero Healthcare Solutions Intrinsic Value
Entero Healthcare Solutions intrinsic value. Entero Healthcare Solutions (ENTERO) median intrinsic value is ₹509.13 from 8 valuation models (range ₹398–₹1392), vs current price ₹1697.10 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Compare with ENTERO fair price to assess whether the stock is under or overvalued.
ENTERO Valuation Methods Summary — DCF, Graham Number & P/E
Entero Healthcare Solutions intrinsic value across 8 models vs current price ₹1697.10 — upside/downside and value range per method. Read ENTERO dividend track record for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹509.13 | ₹407.30 - ₹610.96 | -70.0% | EPS: ₹25.76, Sector P/E: 12x |
| Book Value Method | asset | ₹398.41 | ₹358.57 - ₹438.25 | -76.5% | Book Value/Share: ₹398.41, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹1392.00 | ₹1252.80 - ₹1531.20 | -18.0% | Revenue/Share: ₹1740.00, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹678.84 | ₹610.96 - ₹746.72 | -60.0% | EBITDA: ₹360.00Cr, EV/EBITDA: 6x |
| PEG Ratio Method | growth | ₹509.13 | ₹458.22 - ₹560.04 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹509.13 | ₹458.22 - ₹560.04 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹848.55 | ₹763.69 - ₹933.40 | -50.0% | ROE: 10.3%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹509.13 | ₹458.22 - ₹560.04 | -70.0% | EPS: ₹25.76, BVPS: ₹398.41 |
ENTERO Intrinsic Value vs Market Price — All Valuation Models
Entero Healthcare Solutions fair value range ₹398–₹1392 vs current market price ₹1697.10 across 8 valuation models. For current market price and key ratios, visit ENTERO share price.
ENTERO Intrinsic Value Analysis — Undervalued or Overvalued?
Entero Healthcare Solutions median intrinsic value ₹509.13, current price ₹1697.10 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of ENTERO?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Entero Healthcare Solutions (ENTERO) is ₹509.13 (median value). With the current market price of ₹1697.10, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹398.41 to ₹1392.00, indicating ₹398.41 - ₹1392.00.
Is ENTERO undervalued or overvalued?
Based on our multi-method analysis, Entero Healthcare Solutions (ENTERO) appears to be trading above calculated value by approximately 70.0%.
ENTERO Financial Health — Key Ratios vs Industry Benchmarks
Entero Healthcare Solutions financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 9.65 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 10.3% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 5.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 2.13x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
ENTERO Cash Flow Quality — Operating & Free Cash Flow
Entero Healthcare Solutions operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹96 Cr | ₹-55 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹-77 Cr | ₹-77 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-37 Cr | ₹-389 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-45 Cr | ₹-70 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-35 Cr | ₹-116 Cr | Negative Cash Flow | 3/10 |